Video

Bladder Cancer Clinical Trials

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man.
Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.
Image of doctor.
Image of man.
Image of man with black hair.
Image of man.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Image of man with black hair.
Related Content
Graphic that reads "FDA APPROVED" resembling a stamp of approval
June 12th 2025

FDA Approves UGN-102 For Some With Bladder Cancer

Bridget Hoyt
The FDA has granted approval to UGN-102 for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.
Image of CURE's Cancer Horizons podcast logo: a white microphone with yellow noise lines. Highlights from the 2024 ASCO gastrointestinal and genitourinary cancer conferences.
January 30th 2024

Highlights from the Gastrointestinal and Genitourinary Cancer Conferences

Alex Biese Brielle Benyon
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq: © stock.adobe.com
May 30th 2025

Additive Antihistamines May Improve Metastatic Bladder Cancer Outcomes

Alex Biese
Antihistamines may be associated with survival improvement in patients with metastatic urothelial carcinoma receiving Tecentriq.
cancer horizons podcast logo
December 20th 2023

FDA Approves 3 Treatments, Cancer Vaccine Shows Promise

Alex Biese Brielle Benyon
The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.
Aidixi plus toripalimab met study end points for patients with HER2-expressing urothelial carcinoma: © stock.adobe.com.
May 14th 2025

Aidixi Combination Therapy Improves Survival in Urothelial Carcinoma

Spencer Feldman
Aidixi plus toripalimab met progression-free and overall survival study end points versus chemo for patients with HER2-expressing urothelial carcinoma.
Illustration of bladder.
May 13th 2025

Custom-Made Vaccine Combo Proves Effective in Bladder Cancer

Ryan Scott
Treatment with a custom-made vaccine combination was found to be safe and feasible for patients with bladder cancer, eliciting a strong immune response.